The Effect of a Single BRCA2 Mutation on Cancer in Iceland

Overview

Journal J Med Genet

Specialty Genetics

Date 2002 Jul 13

PMID 12114473

Citations 34

Authors

H Tulinius

G H Olafsdottir

H Sigvaldason

A Arason

R B Barkardottir

V Egilsson

H M Ogmundsdottir

L Tryggvadottir

S Gudlaugsdottir

J E Eyfjord

Affiliations

Soon will be listed here.

Abstract

Objective: To estimate the risk of malignant diseases in families of probands with the same mutation in the BRCA2 gene.

Design: A cohort study using record linkage of a breast cancer family resource and the Icelandic Cancer Registry.

Setting: Iceland.

Subjects: Families of 995 breast cancer patients, from which 887 were tested for a single founder 999del5 mutation; 90 had the mutation and 797 did not.

Results: Relatives of probands with the mutation had significantly increased relative risk (RR) of breast cancer. For first degree relatives, the RR was 7.55 (95% CI 6.04 to 9.03) but was 1.72 (95% CI 1.49 to 1.96) in first degree relatives of probands without the mutation. For prostate and ovarian cancer, the first and second degree relatives of probands with the mutation had a significantly increased RR, but in families of probands without the mutation no significant familial risk was found.

Conclusions: The 999del5 mutation in the BRCA2 gene explains a substantial proportion of familial risk of breast cancer in Iceland, but significant familial risk remains in relatives of probands without the mutation. For prostate and ovarian cancer, the mutation accounts for most of the familiality observed in families of breast cancer patients.

Citing Articles

Gene-based burden tests of rare germline variants identify six cancer susceptibility genes.

Ivarsdottir E, Gudmundsson J, Tragante V, Sveinbjornsson G, Kristmundsdottir S, Stacey S Nat Genet. 2024; 56(11):2422-2433.

PMID: 39472694 DOI: 10.1038/s41588-024-01966-6.

Gastric Cancer Risk and Pathogenesis in and Carriers.

Buckley K, Niccum B, Maxwell K, Katona B Cancers (Basel). 2022; 14(23).

PMID: 36497436 PMC: 9736932. DOI: 10.3390/cancers14235953.

Endoscopic Surveillance in Patients with the Highest Risk of Gastric Cancer: Challenges and Solutions.

Long J, Ebrahimzadeh J, Stanich P, Katona B Cancer Manag Res. 2022; 14:2953-2969.

PMID: 36238953 PMC: 9553156. DOI: 10.2147/CMAR.S277898.

Distinct landscapes of deleterious variants in DNA damage repair system in ethnic human populations.

Qin Z, Huang T, Guo M, Wang S Life Sci Alliance. 2022; 5(9).

PMID: 35595529 PMC: 9122833. DOI: 10.26508/lsa.202101319.

Haploinsufficiency in Telomere Maintenance.

Gunnarsdottir S, Bjarnason H, Thorvaldsdottir B, Paland F, Steinarsdottir M, Eyfjord J Genes (Basel). 2022; 13(1).

PMID: 35052422 PMC: 8775325. DOI: 10.3390/genes13010083.

References

Antoniou A, Pharoah P, McMullan G, Day N, Ponder B, Easton D . Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol. 2001; 21(1):1-18. DOI: 10.1002/gepi.1014. View

Tulinius H, Olafsdottir G, Sigvaldason H, Tryggvadottir L, Bjarnadottir K . Neoplastic diseases in families of breast cancer patients. J Med Genet. 1994; 31(8):618-21. PMC: 1050023. DOI: 10.1136/jmg.31.8.618. View

Tulinius H, Sigvaldason H, Olafsdottir G, Tryggvadottir L . Epidemiology of breast cancer in families in Iceland. J Med Genet. 1992; 29(3):158-64. PMC: 1015889. DOI: 10.1136/jmg.29.3.158. View

Tulinius H, Egilsson V, Olafsdottir G, Sigvaldason H . Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ. 1992; 305(6858):855-7. PMC: 1883041. DOI: 10.1136/bmj.305.6858.855. View

Goldgar D, Easton D, Cannon-Albright L, Skolnick M . Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994; 86(21):1600-8. DOI: 10.1093/jnci/86.21.1600. View

Miki Y, Swensen J, Futreal P, Harshman K, Tavtigian S, Liu Q . A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266(5182):66-71. DOI: 10.1126/science.7545954. View

Thorlacius S, Tryggvadottir L, Olafsdottir G, Jonasson J, Ogmundsdottir H, Tulinius H . Linkage to BRCA2 region in hereditary male breast cancer. Lancet. 1995; 346(8974):544-5. DOI: 10.1016/s0140-6736(95)91383-1. View

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J . Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378(6559):789-92. DOI: 10.1038/378789a0. View

Tavtigian S, Simard J, Rommens J, Couch F, Neuhausen S, Merajver S . The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996; 12(3):333-7. DOI: 10.1038/ng0396-333. View

10.

Gudmundsson J, Johannesdottir G, Arason A, Bergthorsson J, Ingvarsson S, Egilsson V . Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet. 1996; 58(4):749-56. PMC: 1914693. View

11.

Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson J, Tavtigian S . A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996; 13(1):117-9. DOI: 10.1038/ng0596-117. View

12.

Johannesdottir G, Gudmundsson J, Bergthorsson J, Arason A, Agnarsson B, Eiriksdottir G . High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 1996; 56(16):3663-5. View

13.

Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson J, Tryggvadottir L . Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997; 60(5):1079-84. PMC: 1712443. View

14.

Weston A, Godbold J . Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect. 1997; 105 Suppl 4:919-26. PMC: 1470041. DOI: 10.1289/ehp.97105s4919. View

15.

Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjord J . BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med (Berl). 1997; 75(10):758-61. DOI: 10.1007/s001090050162. View

16.

Bergthorsson J, Jonasdottir A, Johannesdottir G, Arason A, Egilsson V, Gayther S . Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum Mutat. 1998; Suppl 1:S195-7. DOI: 10.1002/humu.1380110163. View

17.

Arason A, Jonasdottir A, Barkardottir R, Bergthorsson J, Teare M, Easton D . A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet. 1998; 35(6):446-9. PMC: 1051336. DOI: 10.1136/jmg.35.6.446. View

18.

Thorlacius S, Struewing J, Hartge P, Olafsdottir G, Sigvaldason H, Tryggvadottir L . Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998; 352(9137):1337-9. DOI: 10.1016/s0140-6736(98)03300-5. View

19.

Tulinius H, Sigvaldason H, Olafsdottir G, Tryggvadottir L, Bjarnadottir K . Breast cancer incidence and familiality in Iceland during 75 years from 1921 to 1995. J Med Genet. 1999; 36(2):103-7. PMC: 1734292. View

20.

Healey C, Dunning A, Teare M, Chase D, Parker L, Burn J . A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000; 26(3):362-4. DOI: 10.1038/81691. View